Multiple myeloma in patients younger than 30 years - Report of 10 cases and review of the literature

被引:81
作者
Blade, J [1 ]
Kyle, RA [1 ]
Greipp, PR [1 ]
机构
[1] MAYO CLIN & MAYO FDN,DIV HEMATOL & INTERNAL MED,ROCHESTER,MN 55905
关键词
D O I
10.1001/archinte.156.13.1463
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Objectives: To analyze the presenting clinical and laboratory features and the outcome in a series of 10 patients younger than 30 years with multiple myeloma (MM) and to compare the findings with those reported in the literature. Methods: The records of all patients younger than 30 years with MM who were seen at the Mayo Clinic, Rochester, Minn, between January 1, 1956, and December 31, 1992, were reviewed. Results: The frequency of MM in patients younger than 30 years who were seen at the Mayo Clinic was 0.3%. The clinical and laboratory features were typical of MM in 7 of the 10 patients. Two patients with no increase in bone marrow plasma cells had extensive extramedullary involvement, along with multiple skeletal lesions and the presence of an M protein in the serum and urine samples. One patient had multiple lytic lesions and 10% bone marrow plasma cells with no M component until 6 years after diagnosis, when a sacral plasmacytoma developed and an IgA-kappa protein became apparent. Four patients had initial extramedullary involvement, 3 had renal insufficiency, and 2 had hypercalcemia. Osteolytic lesions were initially found in 6 patients. The M protein was light chain only in 5 patients and IgD in 2. Five patients responded to the initial conventional therapy, and 2 patients with primary resistant disease achieved long-lasting responses with high-dose therapy. The median duration of survival of the patients was 87 months. The proportion of patients who were predicted to be alive at 5 and 10 years was 69% and 31%, respectively. Conclusions: In very young patients with MM, the presenting findings and the response to conventional therapy are similar to those in patients of all ages who have MM. However, a high proportion Of patients had light-chain and IgD myeloma, and 2 patients with primary resistant disease achieved long-lasting responses with high-dose therapy. The survival of our patients was considerably longer than that of patients of all ages with MM.
引用
收藏
页码:1463 / 1468
页数:6
相关论文
共 33 条
[1]
10-YEAR SURVIVAL IN MULTIPLE-MYELOMA [J].
ALEXANIAN, R .
ARCHIVES OF INTERNAL MEDICINE, 1985, 145 (11) :2073-2074
[2]
ANDERSON KC, 1993, BLOOD, V82, P2568
[3]
ATTAL M, 1993, BLOOD S1, V82, P198
[4]
BADWEY TM, 1993, CLIN ORTHOPAEDICS, V294, P290
[5]
BERNSTEIN SC, 1985, CANCER, V56, P2143, DOI 10.1002/1097-0142(19851015)56:8<2143::AID-CNCR2820560844>3.0.CO
[6]
2-8
[7]
ALTERNATING COMBINATION VCMP VBAP CHEMOTHERAPY VERSUS MELPHALAN PREDNISONE IN THE TREATMENT OF MULTIPLE-MYELOMA - A RANDOMIZED MULTICENTRIC STUDY OF 487 PATIENTS [J].
BLADE, J ;
SANMIGUEL, JF ;
ALCALA, A ;
MALDONADO, J ;
SANZ, MA ;
GARCIACONDE, J ;
MORO, MJ ;
ALONSO, C ;
BESALDUCH, J ;
ZUBIZARRETA, A ;
BESSES, C ;
GONZALEZBRITO, G ;
HERNANDEZMARTIN, J ;
FERNANDEZCALVO, J ;
RUBIO, D ;
ORTEGA, F ;
JIMENEZ, R ;
COLOMINAS, P ;
FAURA, MV ;
FONT, L ;
TORTOSA, J ;
DOMINGO, A ;
FONTANILLAS, M ;
ROZMAN, C ;
ESTAPE, J .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (06) :1165-1171
[8]
Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years [J].
Blade, J ;
Kyle, RA ;
Greipp, PR .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (02) :345-351
[9]
LONG-TERM SURVIVAL IN MYELOMATOSIS - A REPORT TO THE MRC WORKING PARTY ON LEUKEMIA IN ADULTS [J].
BUCKMAN, R ;
CUZICK, J ;
GALTON, DAG .
BRITISH JOURNAL OF HAEMATOLOGY, 1982, 52 (04) :589-599
[10]
MULTIPLE-MYELOMA IN A YOUNG WOMAN [J].
CLOUGH, V ;
DELAMORE, IW ;
WHITTAKER, JA .
ANNALS OF INTERNAL MEDICINE, 1977, 86 (01) :117-118